Page 1

BIO - TECHNE RELEASES THIRD QUARTER FISCAL 2021 RESULTS Exhibit 99.1 Minneapolis / May 6 , 2021 / Bio - Techne Corporation ( NASDAQ : TECH ) today reported its financial results for the third quarter ended March 31 , 2021 . ● Third Quarter FY2021 Snapshot Third quarter organic revenue increased by 22 % ( 25 % reported ) to $ 243.6 million and 17 % ( 19 % reported ) in the first nine months of fiscal 2021 to $ 672.0 million . GAAP EPS was $ 1.12 versus $ 0.92 one year ago . Delivered adjusted earnings per share ( EPS ) of $ 1.79 versus $ 1.39 one year ago . Adjusted Operating Margin increased to 40.1 % in the third quarter of fiscal 2021 compared to 36.4 % in the third quarter of fiscal 2020 . Excellent commercial execution in both operating segments with Protein Sciences achieving record organic growth of 24 % and Diagnostics and Genomics delivering 17 % organic growth . Enhanced Bio - Techne's Diagnostics and Genomics segment through the acquisition of Asuragen , Inc. , which closed April 6th , 2021 , adding a portfolio of best - in - class molecular diagnostic and research products and its experienced leadership team . The Company's financial statements are prepared in accordance with accounting principles generally accepted in the United States ( GAAP ) . Adjusted EPS , adjusted earnings , adjusted gross margin , adjusted operating income , adjusted tax rate , organic growth , and adjusted operating margin are non - GAAP measures that exclude certain items detailed later in this press release under the heading " Use of non - GAAP Adjusted Financial Measures . " A reconciliation of GAAP to non - GAAP financial measures is included in this press release . " Congratulations to the entire global Bio - Techne team for delivering another consecutive record quarter , " Said Chuck Kummeth , President and CEO of Bio - Techne . “ Our 22 % organic growth reflects strong execution across geographies and segments , while our financial discipline delivered an impressive adjusted operating margin of 40.1 % . This strength speaks to increasing demand for our portfolio of life science tools and diagnostic solutions , delivering productivity enhancing solutions that are ideal for the current environment and positioning the Company for continued leadership in our platforms as we exit the pandemic . " Kummeth added , “ Our end - markets continued to improve during Q3 , with biopharma remaining strong and academic labs continuing the reopening process . Our ProteinSimple brand of proteomic analytical tools and ACD brand of tissue biopsy products were standouts in the quarter , with these platforms growing approximately + 50 % and + 40 % year - over - year , respectively . The continued rapid adoption of these solutions , combined with our quality reagents and emerging Exosome Dx and Cell and Gene Therapy opportunities , gives us much excitement about what the future still brings for Bio - Techne and all of its stakeholders . "